UK markets close in 7 minutes

Iovance Biotherapeutics, Inc. (0JDK.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
25.14+0.66 (+2.70%)
As of 2:43PM BST. Market open.
Sign in to post a message.
  • s
    scott
    We should be able to make up for the losses and more within the next 15 months. Their first approval really shoul happen by the end of 2022.
  • L
    L
    About time this thing broke out.
  • s
    scott
    Some of the traders definitely seem to know certain key issues ahead of time.
  • J
    Jeffrey
    Ark still has a ton
    Only worry when they sell it all
  • j
    jsmith
    Crazy to be down pre-market, the press release on manufacturing capabilities should have moved us higher.
  • E
    Erik
    Bad for healthcare costs, but the failure of the recent prescription/pharma drug price controls to get through the House of Reps may bode well for IOVA, LYEL, BLUE, TCRX, TCRR and other adoptive immune cell therapy companies whose drug products are likely to be quite expensive.
  • I
    I Get By
    Cathie Wood may be selling but this is more important:

    8-29-21 Medscape: Two Metastatic Lung Cancer Patients Are Disease-Free for 1.5 Years after TILs. "Out of 16 patients, among 13 evaluable patients, 3 had confirmed responses and 11 had reduction in tumor burden. Two patients achieved complete responses that were ongoing 1.5 years following TIL treatment."

    These are lung cancer patients with no other good options.
  • J
    Jeffrey
    Probably up today just because over sold
    TIL is also up
    Once the assays are approved into the 40s

    Then with first 2 approvals 100 and then bought out for 200 after they keeping inching up to 130
  • j
    jsmith
    Well, load up people. I'm selling half my shares for some rebalancing, every time I do this, this price goes up, and no, it doesn't help if I wait. Gotta do it now. You're welcome!
  • G
    Glenn
    Ark sold another 500k plus of shares today. I know some of you think this is trimming, but they are buying FATE hand over fist. So, they are betting on another horse. Own both so I’m hoping both succeed.
  • s
    salayandia
    I heard about IOVA the other day on (http://Rightpicker.com). It’s looking like an interesting play.
  • s
    scott
    The FDA should begin to move on this by the end of the year. Sit tight. Should see approval next year.
  • s
    scott
    This product addresses the huge unmet medical needs and the FDA has no choice but to Eventually move. Not saying any conspiracy theory, but now I have to wonder. Anyway good luck to all the longs who have suffered badly this year.
  • j
    jsmith
    I think we're just treading water for the rest of the year.
  • j
    jsmith
    Well, at least iova is not on a recent list of stocks Cathie is selling.
  • I
    I Get By
    If the treatment has efficacy, all the other problems will eventually be solved and the stock will recover.

    From trial data, though the number of patients are small, these are good numbers, especially consider these patients failed other treatments and ran out of options:

    Response, n (%) (1)
    Cohort 3B
    n=28
    Objective Response Rate 6 (21.4)
    Complete Response (2) 1 (3.6)
    Partial Response 5 (17.9)
    Stable Disease 12 (42.9)
    Progressive Disease 6 (21.4)
    Non-Evaluable 4 (14.3)
    Disease Control Rate 18 (64.3)
    Median Duration of Response Not Reached
    Min, Max (months) 1.2+, 20.7+
  • D
    Daniel
    Iova is among the worst performing biotechs this year.
  • s
    scott
    Even they somehow admit that TIL therapies address much unmet medical needs for a variety of cancer. The data continue to point this way.I have to believe now that they would have moved their #$%$ already and could have even close to approve it if this were from the likes of Pfizer or Merck. There is only so much you can penalize a small new comer and delay it that long. The data Iovance submitted to the FDA on the assay in the past is reasonable although not perfect. Anyway I think they have a very good shot of seeing them lifting things and move towards approval next year.
  • G
    Glenn Myers
    What does everyone think will happen at the conference call today? Besides financial summary that is